Other analysts also recently issued research reports about the company. William Blair reiterated a buy rating on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. Robert W. Baird downgraded Pieris Pharmaceuticals from an outperform rating to a neutral rating and set a $5.00 target price for the company. in a research report on Tuesday, July 30th. HC Wainwright restated a buy rating and issued a $7.00 target price on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. Finally, Zacks Investment Research upgraded Pieris Pharmaceuticals from a hold rating to a buy rating and set a $4.25 target price for the company in a research report on Saturday, November 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $5.42.
Shares of NASDAQ PIRS traded up $0.03 during mid-day trading on Wednesday, reaching $3.87. 414,600 shares of the company’s stock were exchanged, compared to its average volume of 661,692. The firm has a market capitalization of $211.11 million, a price-to-earnings ratio of -7.74 and a beta of 1.26. The firm has a 50-day moving average price of $3.40 and a two-hundred day moving average price of $4.22. Pieris Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $6.04.
In related news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $4.50, for a total value of $225,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.59% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in PIRS. Clear Harbor Asset Management LLC bought a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $47,000. Lindbrook Capital LLC bought a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $37,000. Strs Ohio lifted its position in Pieris Pharmaceuticals by 7.5% in the 2nd quarter. Strs Ohio now owns 112,900 shares of the biotechnology company’s stock worth $530,000 after buying an additional 7,900 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Pieris Pharmaceuticals by 216.5% in the second quarter. JPMorgan Chase & Co. now owns 85,549 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 58,519 shares during the last quarter. Finally, Fosun International Ltd lifted its position in Pieris Pharmaceuticals by 63.8% in the second quarter. Fosun International Ltd now owns 364,693 shares of the biotechnology company’s stock valued at $1,616,000 after purchasing an additional 142,000 shares during the last quarter. Institutional investors own 56.96% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Recommended Story: Support Level
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.